ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq (dolutegravir 50 mg / abacavir 600 mg / lamivudine 300 mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older and weighing at least 40kg. Before initiating treatment with abacavir-containing products, screening for the presence of a genetic marker, the HLA-B*5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.(1) Patients who carry this genetic marker are at high risk of experiencing a hypersensitivity reaction to abacavir.

Triumeq is ViiV Healthcare’s first once-daily single-pill dolutegravir-based regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.

For more details, go to: http://www.viivhealthcare.com/media/press-releases/2014/september/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq.aspx